1/21/2020 8:06:16 AM
Seattle Genetics Achieves Milestone Following EU Approval Of Roche's Polivy For Lymphoma Treatment
12/23/2019 8:02:37 AM
Seattle Genetics Submits Tucatinib NDA To FDA For Locally Advanced Or Metastatic HER2-Positive Breast Cancer
12/18/2019 7:38:14 PM
FDA Grants Accelerated Approval To Astellas' And Seattle Genetics' PADCEV For Most Common Type Of Bladder Cancer
12/18/2019 8:05:38 AM
Seattle Genetics Says FDA Granted Breakthrough Therapy Designation To Tucatinib
12/12/2019 7:13:11 AM
William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform
12/11/2019 9:56:37 AM
Seattle Genetics Announces Positive Trial Results In Locally Advanced Or Metastatic HER2-Positive Breast Cancer
12/9/2019 10:05:24 AM
Seattle Genetics And Takeda Announce Additional Analyses Of ADCETRIS ECHELON-1 And ECHELON-2 Phase 3 Trials
12/2/2019 8:05:08 AM
Seattle Genetics, Astellas Pharma Announce Clinical Collaboration Agreement With Merck
11/25/2019 8:08:23 AM
Seattle Genetics : Canada Oks ADCETRIS -Chemotherapy In Frontline CD30-Expressing Peripheral T-Cell Lymphoma
11/12/2019 6:27:29 PM
Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership
11/7/2019 8:08:24 AM
Seattle Genetics Announces Multiple ADCETRIS Presentations
11/5/2019 8:06:58 AM
Seattle Genetics, BeiGene Announce License Agreement For Advanced Preclinical Product Candidate For Treating Cancer
11/4/2019 11:56:59 PM
Seattle Genetics Responds To Daiichi Sankyo's Complaint For Declaratory Judgment